Aclaris Therapeutics (NASDAQ:ACRS) Shares Down 5.2%

Aclaris Therapeutics, Inc. (NASDAQ:ACRS)’s stock price dropped 5.2% during mid-day trading on Friday . The stock traded as low as $18.60 and last traded at $18.62. Approximately 13,430 shares traded hands during trading, a decline of 99% from the average daily volume of 1,970,723 shares. The stock had previously closed at $19.65.

ACRS has been the topic of several recent research reports. HC Wainwright assumed coverage on Aclaris Therapeutics in a research report on Wednesday, April 21st. They set a “buy” rating on the stock. Zacks Investment Research cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 25th.

The stock has a market capitalization of $966.06 million, a PE ratio of -13.28 and a beta of 0.63. The company has a fifty day simple moving average of $24.08. The company has a current ratio of 9.27, a quick ratio of 9.27 and a debt-to-equity ratio of 0.10.

Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Thursday, May 6th. The biotechnology company reported ($0.57) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.27). Aclaris Therapeutics had a negative net margin of 936.71% and a negative return on equity of 107.60%. As a group, analysts forecast that Aclaris Therapeutics, Inc. will post -1.55 earnings per share for the current year.

In other news, insider Kamil Ali-Jackson sold 15,000 shares of the stock in a transaction dated Wednesday, May 5th. The shares were sold at an average price of $23.98, for a total transaction of $359,700.00. Following the completion of the sale, the insider now directly owns 158,618 shares in the company, valued at $3,803,659.64. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Neal Walker sold 33,260 shares of the stock in a transaction dated Wednesday, June 2nd. The stock was sold at an average price of $21.64, for a total transaction of $719,746.40. Following the sale, the chief executive officer now owns 1,265,442 shares of the company’s stock, valued at $27,384,164.88. The disclosure for this sale can be found here. Insiders have sold 149,507 shares of company stock worth $3,616,811 over the last ninety days. Insiders own 8.20% of the company’s stock.

Several institutional investors have recently bought and sold shares of ACRS. Quantitative Systematic Strategies LLC purchased a new stake in Aclaris Therapeutics in the fourth quarter worth about $193,000. Virtu Financial LLC purchased a new stake in Aclaris Therapeutics in the fourth quarter worth about $141,000. Citigroup Inc. purchased a new stake in Aclaris Therapeutics in the fourth quarter worth about $275,000. Ghost Tree Capital LLC purchased a new stake in Aclaris Therapeutics in the fourth quarter worth about $4,206,000. Finally, Wells Fargo & Company MN lifted its holdings in Aclaris Therapeutics by 2,606.3% in the fourth quarter. Wells Fargo & Company MN now owns 32,936 shares of the biotechnology company’s stock worth $213,000 after buying an additional 31,719 shares during the period. Institutional investors own 87.24% of the company’s stock.

About Aclaris Therapeutics (NASDAQ:ACRS)

Aclaris Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation.

See Also: Does a trade war provide a risk to the global economy?

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.